Originally, the patent claimed many genetically modified animal species, from mice to great apes. These animals are to be genetically engineered for experimental purposes so that they develop symptoms of Parkinson's disease.

Ethical reasons were decisive for the EPO's current decision. According to the expected animal suffering is not offset by any proven substantial medical benefit as required by the rules of European patent law.

Source and further information:
https://www.testbiotech.org/aktuelles/erfolg-bei-einspruch-gegen-patent-auf-gentechnisch-veraenderte-parkinson-affen